This press release says good things about the future of this company, funding will continue 
and revenues will build.

~~ dimar


Response Biomedical Announces Funded Development Program with Roche Diagnostics to
Expand Cardiovascular Product Offerings - February 11, 2009 4:00PM ET

Response Biomedical Corporation (TSX: RBM, OTCBB: RPBIF) announced that Roche
Diagnostics has agreed to fund two new projects aimed at strengthening the
commercial success of the Response cardiovascular line of products that Roche is
expected to market in North America, beginning in this quarter. Response Biomedical
and Roche Diagnostics signed a strategic partnership in June 2008 to commercialize
Response's cardiovascular tests.

The first project approved for funding is to complete a submission for a CLIA-waiver
for the RAMP(R) NT-proBNP assay. NT-proBNP is used in the diagnosis of heart
failure. The RAMP(R) NT-proBNP assay has been well accepted as a rapid, accurate
test to expedite this diagnosis. In an effort to expand the availability of this
system to physician's offices and smaller group practices that are only licensed to
perform simple (CLIA-waived) tests, Roche and Response will combine efforts to
complete a clinical trial to support CLIA-waived status for the RAMP(R) NT-proBNP
assay. The trial is expected to be completed and the CLIA-waiver submission made to
the FDA in 2009.

"The availability of a CLIA-waived NT-proBNP test will open the doors to the use of
the Cardiac 200 system in small practices and physician's offices, and will
complement current CLIA-waived Roche offerings for blood glucose and oral
anticoagulation monitoring," said Bernd Schnakenberg, Head of Decentralized
Solutions, Roche Professional Diagnostics.

The next project Response will undertake, is a next-generation Troponin I (TnI)
assay development. Troponin I is a critical part of the diagnosis of heart attacks
or acute myocardial infarction, especially for the more than 50 percent of cases
where an electrocardiogram is inconclusive. The development of the improved RAMP(R)
TnI test will re-align the results obtained to more closely reflect those obtained
on the most commonly used central laboratory analyzers.

"We are very excited about expanding our collaboration with Roche Diagnostics," said
S. Wayne Kay, Chief Executive Officer, Response Biomedical. "Roche is one of the
largest in vitro diagnostics companies in the world, and we could not ask for a
stronger partner to commercialize our cardiovascular product line. We have already
begun work on these two important projects and Roche's support will allow us the
ability to focus key resources to advance the cardiovascular product line while
conserving cash outlays by Response."

The RAMP(R) cardiovascular product line includes NT-proBNP, Troponin I, CK-MB and
Myoglobin tests.

About Response Biomedical

Response Biomedical develops, manufactures and markets rapid on-site diagnostic
tests for use with its RAMP(R) Platform for clinical and environmental applications.
RAMP(R) represents a new paradigm in diagnostics that provides high sensitivity and
reliable information in minutes. It is ideally suited to both point-of-care testing
and laboratory use. The RAMP(R) system consists of a Reader and single-use
disposable test cartridges, and has the potential to be adapted to more than 250
medical and non-medical tests currently performed in laboratories. RAMP(R) clinical
tests are commercially available for the early detection of heart attack, congestive
heart failure and influenza.

In the non-clinical market, RAMP(R) Tests are currently provided for the
environmental detection of West Nile Virus, and Biodefense applications including
the rapid on-site detection of anthrax, smallpox, ricin and botulinum toxin. Several
other product applications are under development. Response has achieved CE Marking
for its Reader and clinical tests and its Quality Management System is registered to
ISO 13485: 2003 and ISO 9001: 2000. The RAMP(R) Influenza A/B Assay and RAMP 200
reader are not yet licensed for clinical use in Canada.

Response Biomedical is a publicly traded company, listed on the TSX under the
trading symbol "RBM" and quoted on the OTC Bulletin Board under the symbol "RPBIF".
For further information, please visit the Company's website at www.responsebio.com.

Statements contained in this press release relating to future results, events or
developments, for example, statements containing the words "believes," "may,"
"could", "plans," "will," "estimate," "continue," "anticipates," "intends,"
"expects", "goal" and similar expressions, are "forward-looking statements" or
"forward-looking information" under applicable United States and Canadian securities
laws. Forward-looking statements or information may involve, but are not limited to,
comments with respect to our planned activities, business plan and strategies and
their future implementation, and our expectations for our financial condition and
the results of, or outlook for, our business operations generally. Forward-looking
statements or information are subject to the related assumptions made by us and
involve known and unknown risks, uncertainties and other factors that may cause
actual results, events or developments to be materially different from those
expressed or implied b
 y such statements or information.

Many of such risks, uncertainties and other factors form part of our underlying
assumptions, and include, among other things, financial risks that would affect our
operations such as our available working capital and cash flows and whether and for
how long available funds will be sufficient to fund our operations and our ability
to raise additional capital as and when needed; our need for substantial additional
funding to conduct research and development and commercialization activities; our
ability to establish, and our dependence upon, relationships with strategic alliance
partners to develop and commercialize products; technological changes that impact
our existing products or our ability to develop and commercialize our products; our
ability to obtain and enforce timely patent and other intellectual property
protection for our technology and products; liability for patent, product liability
and other claims asserted against us; commercialization limitations imposed by pat
 ents owned or controlled by third parties; our ability to retain, and our reliance
upon, third party suppliers, manufacturers, distributors and alliance partners; our
ability to effectively and efficiently manage the planned growth of our operations;
our ability to profitably sell our products at prices that would be acceptable to
third-party reimbursement programs; competition including competition from others
with significantly more resources; market acceptance of our products and the size
of our markets; changes in business strategy or development plans; changes in, or
the failure to comply with, governmental regulations; and other factors referenced
in our annual report, our Annual Information Form (AIF) (Form 40-F in the U.S.) and
other filings with Canadian and United States securities regulatory authorities.

Given these uncertainties, assumptions and risks, readers are cautioned not to place
undue reliance on such forward-looking statements or information. We disclaim any
obligation to update, or to publicly announce any revisions to, any such statements
or information to reflect future results, events or developments, except as required
by law.

SOURCE: Response Biomedical Corp.

Response Biomedical Contacts: Bill Wickson, Director, Investor Relations, Response
Biomedical Corporation, Tel (604) 456-6073, Email: [email protected]